Humacyte, Inc. (HUMA) Cash Flow Statement
Humacyte, Inc. (HUMA) generated -$97.2M of operating cash flow over the twelve months to 2026-06-30, spent $367000 on capital expenditure and had free cash flow of -$97.6M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
HUMAHumacyte, Inc.Follow HUMA — free
—
Price chart with a free account
- Market cap
- 121.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 6 Nov, in 12 days
| Line | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|
| Operating cash flow | -105.0 | -97.2 | |
| Capital expenditure | 0.9 | -0.4 | |
| Free cash flow | -105.9 | -97.6 | |
| Dividends paid | 0.0 | — | |
| Stock-based compensation | 9.8 | — |
USD millions · SEC XBRL
Humacyte, Inc. — questions
- What is Humacyte, Inc.'s operating cash flow?
- -$97.2M over the twelve months to 2026-06-30.
- How much does Humacyte, Inc. spend on capital expenditure?
- $367000 over the twelve months to 2026-06-30.
- What is Humacyte, Inc.'s free cash flow?
- -$97.6M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Humacyte, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.